Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu

EJNMMI Radiopharmacy and Chemistry

Table 2 Absorbed doses in the tumour and normal organs in mice with subcutaneous PANC-1 xenografts treated with RICs

^aEstimated using \( D=\sum {\overset{\sim }{A}}_S\times {S}_{T\leftarrow S} \), where \( {\overset{\sim }{A}}_S \) is the time-integrated activity (Bq × sec) in the source organ (see Supplementary Fig. S2), and S is the Snyder factor for mouse organs (Bitar et al., 2007). The tumour dose was estimated using the sphere model in OLINDA/EXM dosimetry software and the tumour size (Stabin et al., 2005)
^bAbsorbed dose for NOD/SCID mice injected i.v. (tail vein) with three amounts (10 MBq; 10 μg; ~ 0.07 nmoles) of ¹¹¹In-labeled RICs separated by 3 weeks
^cAbsorbed dose for NRG mice injected i.v. (tail vein) with a single amount (6 MBq; 10 μg; ~ 0.07 nmoles) of ¹⁷⁷Lu-labeled RICs